Exicure, Inc. (XCUR) stock
XCURNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.04−0.04 (-3.70%)
Close on Nov 18, 2026Market cap $6.81MP/E –Yield –
Exicure price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Exicure's price to sales ratio was 126.0× on Apr 30, 2025, against 0.2× a year earlier. Over the last 5 years it ranged from 0.2× to 259.0×, with a median of 11.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 126.0× | +66.6 |
| 2024 | Dec 31, 2024 | 59.4× | +59.2 |
| 2023 | Dec 29, 2023 | 0.2× | −0.4 |
| 2022 | Dec 30, 2022 | 0.6× | −26.6 |
| 2021 | Oct 29, 2021 | 27.2× | +18.0 |
| 2020 | Dec 31, 2020 | 9.2× | −209.9 |
| 2019 | Dec 31, 2019 | 219.1× | +148.0 |
| 2018 | Dec 31, 2018 | 71.2× | – |
See a number that looks wrong?